Cna Financial Corp Vir Biotechnology, Inc. Transaction History

Cna Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$18.26 - $31.1 $63,910 - $108,850	-3,500 Reduced 25.56%	10,192 $197,000
Q2 2022 Aug 09, 2022	SELL	$19.08 - $26.7 $35,298 - $49,395	-1,850 Reduced 11.9%	13,692 $349,000
Q1 2022 May 10, 2022	BUY	$21.19 - $40.01 $37,930 - $71,617	1,790 Added 13.02%	15,542 $400,000
Q4 2021 Feb 11, 2022	BUY	$30.97 - $54.03 $54,507 - $95,092	1,760 Added 14.68%	13,752 $576,000
Q3 2021 Nov 12, 2021	BUY	$34.9 - $54.54 $1,745 - $2,727	50 Added 0.42%	11,992 $522,000
Q2 2021 Aug 12, 2021	BUY	$38.75 - $51.0 $41,462 - $54,570	1,070 Added 9.84%	11,942 $565,000
Q1 2021 May 14, 2021	SELL	$26.34 - $83.07 $181,219 - $571,521	-6,880 Reduced 38.76%	10,872 $557,000
Q4 2020 Feb 12, 2021	BUY	$25.51 - $43.38 $140,815 - $239,457	5,520 Added 45.13%	17,752 $475,000
Q3 2020 Nov 12, 2020	BUY	$28.28 - $53.6 $36,764 - $69,680	1,300 Added 11.89%	12,232 $420,000
Q2 2020 Aug 13, 2020	BUY	$27.89 - $47.86 $304,893 - $523,205	10,932 New	10,932 $448,000

231

90.1M

1.28M

235K

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.27B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.